From the perspective of the Hong Kong stock market, several innovative drug-related indices have seen year-to-date gains exceeding 100%. As key indices in the A-share market collectively rebound and trading congestion in the innovative drug sector significantly increases, capital divergence intensifies, leading to consecutive adjustments in Hong Kong’s innovative drug sector.

Meanwhile, benefiting from the high prosperity of the innovative drug sector, recent CXO performance trends continue to recover. CDMO, CRO, research services, Pharma, Biotech, and other innovative drug-related industries are all part of the innovative drug industry chain and are expected to continue benefiting.

According to Aijian Securities’ analysis, a series of international academic conferences, such as the World Conference on Lung Cancer (WCLC, 9/6-9/9), the European Respiratory Society Annual Congress (ERS, 9/27-10/1), the European Society for Medical Oncology Congress (ESMO, 10/17-10/21), the American Society of Hematology Annual Meeting (ASH, 12/6-12/9), and the San Antonio Breast Cancer Symposium (SABCS, 12/10-12/13), will open intensively. Several Chinese innovative drug companies have announced that important research results will be published, and China’s innovative drugs are expected to usher in a new round of data catalysis.

Related ETFs:

Hong Kong Stock Connect Healthcare ETF (520510): Focuses on CXO+AI healthcare themes, with WuXi-related holdings exceeding 24%.

Hang Seng Healthcare ETF (159892): Focuses on innovative drug themes, the largest under the same index with good liquidity.